Additional Information

Shareholder Information
AstraZeneca PLC share listings and prices
2011

2012

2013

2014

2015

Ordinary Shares in issue millions

At year end

1,292

1,247

1,257

1,263

1,264

Weighted average for year

1,361

1,261

1,252

1,262

1,264

Stock market price per Ordinary Share

Highest (pence)

3194.0

3111.5

3612.0

4823.5

4863.0

Lowest (pence)

2543.5

2591.0

2909.5

3549.5

3903.5

At year end (pence)

2975.0

2909.5

3574.5

4555.5

4616.5

2011
%

2012
%

2013
%

2014
%

2015
%

1 250

0.6

0.6

0.5

0.5

0.5

251 500

0.7

0.7

0.6

0.6

0.6

501 1,000

0.8

0.8

0.8

0.7

0.7

1,001 5,000

1.2

1.1

1.1

1.0

0.9

5,001 10,000

0.2

0.2

0.2

0.2

0.2

10,001 50,000

1.0

1.0

1.0

1.0

0.9

50,001 1,000,000

13.8

12.6

12.3

13.3

13.0

Over 1,000,0001

81.7

83.0

83.5

82.7

83.2

Percentage analysis of issued share capital at 31 December

By size of account
Number of Ordinary Shares

Includes Euroclear and ADR holdings.

At 31 December 2015, the Company had

97,260 registered holders of 1,264,122,670
Ordinary Shares. There were 104,150
holders of Ordinary Shares held under
the Euroclear Services Agreement,
representing 10.8% of the issued share
capital of the Company and approximately
172,000 holders of ADSs, representing
10.8% of the issued share capital of the
Company. With effect from 27 July 2015,
the Companys ADS ratio changed to two
ADSs per one Ordinary Share. The former
ratio was one ADS per one Ordinary Share.
With effect from 6 February 2015, Citibank,
N.A. (Citibank) succeeded JPMorgan
Chase Bank (JPMorgan) as depositary
of the ADSs.
In 1999, in connection with the merger
between Astra and Zeneca through which
the Company was formed, the Companys
share capital was redenominated in US
dollars. On 6 April 1999, Zeneca shares
were cancelled and US dollar shares issued,
credited as fully paid on the basis of one
dollar share for each Zeneca share then
held. This was achieved by a reduction of

240

capital under section 135 of the Companies

Act 1985. Upon the reduction of capital
becoming effective, all issued and unissued
Zeneca shares were cancelled and the sum
arising as a result of the share cancellation
credited to a special reserve, which was
converted into US dollars at the rate of
exchange prevailing on the record date. This
US dollar reserve was then applied in paying
up, at par, newly created US dollar shares.
At the same time as the US dollar shares
were issued, the Company issued 50,000
Redeemable Preference Shares for cash,
at par. The Redeemable Preference Shares
carry limited class voting rights, no dividend
rights and are capable of redemption, at par,
at the option of the Company on the giving
of seven days written notice to the
registered holder of the Redeemable
Preference Shares.
A total of 826 million Ordinary Shares were
issued to Astra shareholders who accepted
the merger offer before the final closing
date, 21 May 1999. The Company received
acceptances from Astra shareholders

AstraZeneca Annual Report and Form 20-F Information 2015

representing 99.6% of Astras shares and

the remaining 0.4% was acquired in 2000,
for cash.
Since April 1999, following the merger of
Astra and Zeneca, the principal markets for
trading in the shares of the Company are
the LSE, the SSE and the NYSE. The table
overleaf sets out, for 2014 and 2015, the
reported high and low share prices of the
Company, on the following bases:
>> For shares listed on the LSE, the reported
high and low middle market closing
quotations are derived from the Daily
Official List.
>> For shares listed on the SSE, the high and
low closing sales prices are as stated in
the Official List.
>> For ADSs listed on the NYSE, the
reported high and low sales prices are as
reported by Dow Jones (ADR quotations).